Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study Testing a New Heart Scan Method to Improve Pacemaker Treatment for Heart Failure
Sponsor: King's College London
Summary
Cardiac resynchronization therapy (CRT) is a device treatment for patients with heart failure which cannot be managed by medications alone. CRT can help the heart contract more efficiently and improve the pumping function. However, many patients do not benefit from this treatment. Therefore, a better selection tool will help us to determine the most suitable patients to receive this treatment. A new measure of pumping function of the heart called: first-phase ejection fraction or EF1 has been shown a good tool to select suitable patients for CRT. EF1 is a sensitive measurement of heart function and can be easily measured by echocardiography (an ultrasound heart scan). The purpose of this study is to examine whether this new measurement (EF1) can predict outcomes and response to CRT treatment.
Official title: Evaluation of First-Phase Ejection Fraction to Guide Cardiac Resynchronization Therapy - A Randomised Controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2025-08-01
Completion Date
2030-07-31
Last Updated
2025-08-03
Healthy Volunteers
No
Interventions
EF1 guided CRT optimisation
In the EF1-guided optimisation group, the settings of the CRT device are adjusted to maximise early heart pumping efficiency, measured by a parameter called first-phase ejection fraction (EF1). Depending on the patient's heart rhythm, either the timing between heart chambers (AV or VV delay) is adjusted in small steps. The device setting that gives the best EF1 reading is chosen to help improve the heart's response to CRT.
Standard of Care (SOC)
This group will receive standard of care for their health condition and CRT management.
Locations (1)
Guy's and St. Thomas' NHS Foundation Trust
London, United Kingdom